Valuation: Palisade Bio, Inc.

Market Cap 329M 286M 266M 244M 461M 31.4B 469M 3.14B 1.23B 15.63B 1.24B 1.21B 52.42B P/E 2026 *
-7.98x
P/E 2027 * -6.74x
Enterprise Value 235M 204M 190M 174M 329M 22.41B 334M 2.24B 879M 11.16B 882M 862M 37.41B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.25%
Yield 2026 *
-
Yield 2027 * -
1 day-3.32%
1 week-2.82%
1 month-3.81%
3 months-4.77%
6 months+27.18%
Current year-19.36%
1 week 1.86
Extreme 1.855
2.04
1 month 1.84
Extreme 1.84
2.22
Current year 1.45
Extreme 1.45
2.86
1 year 0.53
Extreme 0.53
2.86
3 years 0.53
Extreme 0.53
31.95
5 years 0.53
Extreme 0.53
2,400
10 years 0.53
Extreme 0.53
8,182.5
Manager TitleAgeSince
Chief Executive Officer 68 2022-10-09
President 48 -
Chief Tech/Sci/R&D Officer - 2025-10-27
Director TitleAgeSince
Chairman 67 2024-02-13
Director/Board Member 55 2018-12-31
Director/Board Member 68 2023-02-01
Date Insider Type Main position Quantity % Market Cap.
7/9/26 Buy

Director

25,000 0.0151%
7/7/26 Buy

Director

30,000 0.0181%
7/7/26 Sell

Chief Executive Officer

-147,064 0.0887%
Change 5-day change 1-year change 3-year change Capi.($)
-3.32%-2.82%+87.62%-94.04% 329M
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+411.96%+495.33% 39.87B
-1.16%+12.96%+28.81%+7.25% 38.68B
-1.88%-3.03%+5.69%+53.00% 35.13B
-1.74%+5.12%+14.44%+41.77% 29.79B
-0.21%-4.04%+36.40%+125.75% 16.11B
-2.85%-3.92% - - 16.08B
-0.64%+2.65%+3.40%+13.11% 13.61B
-1.19%-1.32%-1.73%-34.37% 12.62B
Average -1.68%+0.67%+64.99%+68.79% 25.07B
Weighted average by Cap. -1.60%+2.03%+79.79%+108.33%

Financials

2026 *2027 *
Net sales - -
Net income -50.56M -43.95M -40.91M -37.56M -70.93M -4.83B -72.03M -482M -189M -2.4B -190M -186M -8.06B -64.87M -56.39M -52.49M -48.19M -91M -6.19B -92.41M -619M -243M -3.08B -244M -238M -10.34B
Net Debt -94.2M -81.89M -76.22M -69.98M -132M -8.99B -134M -898M -353M -4.48B -354M -346M -15.01B -331M -288M -268M -246M -465M -31.62B -472M -3.16B -1.24B -15.74B -1.24B -1.22B -52.78B
Logo Palisade Bio, Inc.
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.
Employees
-
Date Price Change Volume
26-07-31 US$1.895 -3.32% 1,853,422
26-07-30 US$1.960 -.--% 1,014,651
26-07-29 US$1.960 -2.97% 1,659,590
26-07-28 US$2.020 -0.49% 2,052,443
26-07-27 US$2.030 +4.10% 1,431,695
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.895USD
Average target price
10.22USD
Spread / Average Target
+439.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PALI Stock